Ungated Post | 06 Mar 2020

Making cells better: Complex challenges drive innovation in cell and gene therapy manufacturing

The processes required for C&GT manufacture are wholly new and extremely complex. As production and delivery of these new therapies to patients are still nascent, biopharmaceutical companies will need to harness new technological advances and innovate continuously in the manufacturing process.

Large capital investments in the industry are likely to bring breakthroughs in the coming years that will standardise processes, simplify delivery logistics, boost efficiency, and increase competition.


Read the full report


Our Thought Leadership team produces original, evidence-based research made accessible to decision-makers and opinion leaders. Principals for this project included:

Oxford Economics’ team is expert at applying advanced economic tools that provide valuable insights into today’s most pressing business, financial, and policy issues.

To find out more about our capabilities, contact:

EMEA
Paul Donnelly
020 3910 8000
Email

Americas
Jeffrey Klonoski
+1 646 503 3048
Email

Asia
Christie Tang
+852 3974 8841
Email

Related Services

Post

Supporting the U.S. economy: the economic impact of Reckitt in the U.S.

Consulting Report Making cells better: Complex challenges drive innovation in cell and gene therapy manufacturing You might be interested in

Find Out More

Post

Ensuring that the UK can capture the benefits of quantum computing

Consulting Report Making cells better: Complex challenges drive innovation in cell and gene therapy manufacturing Commissioned by IBM and Oxford Quantum Circuits You might be interested in

Find Out More

Post

Beer’s Global Economic Footprint

Consulting Report Making cells better: Complex challenges drive innovation in cell and gene therapy manufacturing Commissioned by World Brewing Alliance You might be interested in

Find Out More